Key result
Comprehensive glycemic, BP, and lipid management slows diabetic nephropathy progression.
This review highlights the current standard of care for diabetic nephropathy and the pressing need for novel therapeutic agents to halt disease progression.
Multifaceted care remains standard for diabetic nephropathy; leaves open urgent need for novel agents to halt progression.
Diabetic nephropathy remains the foremost common cause of endstage nephritic disease worldwide. The present standard of medical care for diabetic kidney disease involves rigorous vital sign management via blockade of the renin–angiotensin system and control of hyperglycemia. Despite these methods, diabetic kidney disease continues to be seen to progress unrelentingly. A pressing would like for novel therapeutic agents have burning endless basic science research outcomes and clinical trials within the look for an additional specific medical care. Throughout the method, solely a couple of accessory agents have shown experimental promise and even fewer have incontestable effect in clinical trials. Treatment in diabetic nephropathy include glycemic management, treatment of hypertension, lipidemia, cease of smoking, protein restriction and renal replacement therapy. Complex approach includes combined medical care targeting hyperglycemia, high blood pressure, microalbuminuria, and dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Nikhila Vengala (2017) conducted a review in Diabetic nephropathy. Diabetic nephropathy requires a complex treatment approach including glycemic management, blood pressure control, lipid management, and lifestyle modifications to slow disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: